头孢地尔治疗期间大肠埃希菌耐药进展与blaNDM-5拷贝数及基因表达增加相关
本文报道一例急性淋巴细胞白血病患者,其产NDM-5大肠埃希菌腹腔感染在头孢地尔治疗约2周后出现耐药。通过全基因组测序、mRNA表达研究和EDTA抑制分析5株连续临床分离株,发现blaNDM-5拷贝数增加及表达上调与头孢地尔耐药相关,患者最终经头孢他啶-阿维巴坦联合氨曲南治愈。
要点
- 头孢地尔治疗中可出现blaNDM-5拷贝数增加导致的获得性耐药。
- 产NDM-5肠杆菌感染可考虑头孢他啶-阿维巴坦联合氨曲南治疗。
- 治疗期间需监测头孢地尔对产NDM菌株的疗效。
核心结论
- 产NDM肠杆菌可能通过转位事件增加blaNDM基因拷贝数来逃避头孢地尔介导的细胞死亡。
- blaNDM-5表达增加对头孢地尔耐药的具体频率尚需研究。
研究设计与样本
- 病例报告,对一例急性淋巴细胞白血病合并产NDM-5大肠埃希菌腹腔感染患者进行连续5株临床分离株分析。
- 采用全基因组测序、mRNA表达研究和EDTA抑制分析探究耐药机制。
主要发现
- 5株分离株均检出blaNDM-5基因。
- 头孢地尔对分离株1-2、3、4-5的最低抑菌浓度分别为2、4和>32 μg/mL。
- 分离株1-3含单拷贝blaNDM-5,分离株4和5在IncFIA/FIB/IncFII质粒上分别有5和10拷贝。
- 分离株4和5的blaNDM-5 mRNA表达量分别为分离株1的1.7倍和2.8倍。
- 头孢他啶-阿维巴坦联合氨曲南药敏纸片协同试验显示所有分离株抑菌圈扩大。
关键数值与推荐
- 头孢地尔MIC从2 μg/mL升至>32 μg/mL,对应blaNDM-5拷贝数从1增至10。
- 分离株4和5的blaNDM-5表达较分离株1分别升高1.7倍和2.8倍。
临床怎么用
- 对产NDM-5肠杆菌感染使用头孢地尔治疗时应警惕耐药快速进展。
- 头孢他啶-阿维巴坦联合氨曲南可作为产NDM-5肠杆菌感染的治疗选择。
局限性
- 本文为单病例报告,结论需在更大样本中验证。
- blaNDM-5表达增加导致头孢地尔耐药的频率尚不明确。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: As cefiderocol is increasingly being prescribed in clinical practice, it is critical that we understand key mechanisms contributing to acquired resistance to this agent. METHODS: We describe a patient with acute lymphoblastic leukemia and a New Delhi metallo-ß-lactamase (NDM)-5-producing Escherichia coli intra-abdominal infection in whom resistance to cefiderocol evolved approximately 2 weeks after the start of treatment. Through whole-genome sequencing (WGS), messenger RNA expression studies, and ethylenediaminetetraacetic acid inhibition analysis, we investigated the role of increased NDM-5 production and genetic mutations contributing to the development of cefiderocol resistance, using 5 sequential clinical E. coli isolates obtained from the patient. RESULTS: In all 5 isolates, blaNDM-5 genes were identified. The minimum inhibitory concentrations for cefiderocol were 2, 4, and >32 μg/mL for isolates 1-2, 3, and 4-5, respectively. WGS showed that isolates 1-3 contained a single copy of the blaNDM-5 gene, whereas isolates 4 and 5 had 5 and 10 copies of the blaNDM-5 gene, respectively, on an IncFIA/FIB/IncFII plasmid. These findings were correlated with those of blaNDM-5 messenger RNA expression analysis, in which isolates 4 and 5 expressed blaNDM-5 1.7- and 2.8-fold, respectively, compared to, isolate 1. Synergy testing with the combination of ceftazidime-avibactam and aztreonam demonstrated expansion of the zone of inhibition between the disks for all isolates. The patient was successfully treated with this combination and remained infection free 1 year later. CONCLUSIONS: The findings in our patient suggest that increased copy numbers of blaNDM genes through translocation events are used by Enterobacterales to evade cefiderocol-mediated cell death. The frequency of increased blaNDM-5 expression in contributing to cefiderocol resistance needs investigation.
引用
- Simner PJ, Mostafa HH, Bergman Y, et al. Progressive Development of Cefiderocol Resistance in Escherichia coli During Therapy is Associated With an Increase in blaNDM-5 Copy Number and Gene Expression. Clin Infect Dis. 2022. PMID: 34618008. doi:10.1093/cid/ciab888
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。